Worldwide News

The latest sponsored DDW Sitting Down With podcast features Paul Wylie, Director of Multiplex at Abcam looking at enhancing the role of multiplexing in high-throughput screening.  Among the topics Lu Rahman will be discussing with Wylie will be the key challenges scientists face with biomarker and drug discovery and how high-throughput screening can help alleviate […]

Mutations in the ARID1A gene are present in more than 50% of ovarian clear cell carcinomas (OCCC), for which effective treatments are lacking. Scientists at The Wistar Institute discovered that loss of ARID1A function enhances a cellular stress response pathway that promotes survival of cancer cells, which become sensitive to pharmacological inhibition of this pathway.   […]

In what BenevolentAI considers a move that deepens its drug discovery and development expertise on its board, Dr John Orloff has been appointed as a Non-Executive Director. Dr Orloff joins the BenevolentAI board as it advances plans to scale its AI platform, partnerships and drug portfolio. DDW’s Megan Thomas speaks with Dr Orloff about his career and the future of […]

Scientists from the University of Oxford and the Ludwig Institute for Cancer Research are building on the Oxford-AstraZeneca vaccine for SARS-CoV-2 to develop a vaccine to treat cancer.   Researchers have designed a two-dose therapeutic cancer vaccine using Oxford’s viral vector vaccine technology. When tested in mouse tumour models, the cancer vaccine increased the levels of anti-tumour T cells […]

This is the latest episode of the free DDW podcast: “Opportunities to improve drug discovery systems”. It covers two articles written for Volume 22, Issue 1 – Winter 2020/21 of the Drug Discovery World Magazine.   The first article is titled “Precision control of protein release to reconfigure bioprocessing and cell-based assays”, where the authors Dr […]

An international study led by McMaster University scientists and published in The British Medical Journal show a minority of people living with chronic pain who try medical cannabis may experience important relief and the risk of side effects is typically small.  Data from 32 randomised controlled trials showed that use of non-inhaled medical cannabis versus placebo resulted in small […]

The last year has seen virology take the forefront of the drug discovery sector as experts collaborated and worked with unprecedented speed to develop a Covid-19 vaccine to reach an end to the global coronavirus pandemic. But other industries have continued to work tirelessly to develop treatments for other diseases and viruses, from Alzheimer’s treatment […]

Qingyun Liu, leader of a preclinical development core where researchers can test the effectiveness of large molecule drug candidates for novel cancer treatments, has been awarded an approximately $4 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).  Liu is Professor of Precision Biomedicine with the Brown Foundation Institute of Molecular Medicine for […]

Results from the large, randomised COAST Phase II trial showed oleclumab, an anti-CD73 monoclonal antibody, or monalizumab, an anti-NKG2A monoclonal antibody, in combination with Imfinzi (durvalumab) improved progression-free survival (PFS) and objective response rate (ORR) compared to Imfinzi alone in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation […]

The route to market for biosimilars places strong emphasis on characterisation tools for establishing comparability between biosimilar and innovator products.   Addressing analytical challenges in fast-forwarding biosimilar development processes requires Implementing sophisticated analytical instruments with advanced technologies. The ICH Q6B, cited by both EMA and FDA, highlights electrophoretic data as an important part of the molecule’s full structural characterisation.   […]